MacroGenics

MacroGenics, Inc. is a clinical-stage biopharmaceutical company engaged in discovering and developing antibody-based therapeutics designed to modulate the human immune response for the treatment of cancer. Its product pipeline includes Margetuximab, Flotetuzumab, Retifanlimab, Enoblituzumab, Tebotelimab, MGC018, MGD019, IMGC936, and MGD014 for infectious diseases. The company was founded by Scott E. Koenig, Jeffrey V. Ravetch, LeRoy E. Hood, Ruedi Aebersold, and Alan Aderem on August 14, 2000 and is headquartered in Rockville, MD.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

MacroGenics reports revenue growth and promising clinical updates in Q4

MacroGenics delivered strong financial performance with revenue growth and cost reductions in 2022.
The company faces challenges in study modifications, dose optimization, and patient evaluation for its key products.
Opportunities lie in expanding product studies, strategic partnerships, and optimizing treatment efficacy.
Overall, MacroGenics shows promise in financial stability, product development, and market positioning.

MacroGenics reports Q1 revenue growth amidst net loss challenges

MacroGenics showed mixed financial performance in Q1 2023 with revenue growth but a significant net loss.
The company's strengths lie in its anticipated cash runway, FDA approvals, and expected milestone payments.
Challenges include managing expenses, improving financial performance, and addressing analyst inquiries.
Opportunities exist in revenue growth, clinical programs, FDA approvals, and strategic partnerships.

MacroGenics reports Q2 results, projects strong pipeline growth ahead

MacroGenics' Q2 2023 performance reflects mixed financial results but strong progress in pipeline development and strategic partnerships.
The company's financial stability, ongoing innovation, and revenue potential position it well for future growth and value creation.
Challenges in data disclosure, enrollment criteria, and dose optimization require careful navigation, but present opportunities for market expansion and program enhancement.

MacroGenics reports improved Q3 earnings, eyes strategic partnerships for growth

MacroGenics demonstrated improved financial performance in Q3 2023, with a focus on cost management and strategic pipeline advancements.
The company's efforts to secure non-dilutive capital, explore partnerships, and drive innovation in ADC development position it for future growth.
Challenges lie in revenue generation, market differentiation, and resource allocation, but opportunities exist in collaborations, tumor type expansion, and technological advancements.

MacroGenics reports revenue decline but advances in clinical programs

MacroGenics faced a decline in revenue but made progress in its clinical programs and pipeline advancements.
Challenges include data transparency, patient enrollment, and managing treatment side effects.
Opportunities lie in potential Phase III trials, revenue growth prospects, and advancements in patient treatment.

MacroGenics reports strong Q1 results, eyes expansion and combination therapies

MacroGenics' Q1 2024 performance showed promising results with strong revenue and ongoing research advancements.
The company's focus on expanding studies, improving tolerability, and exploring combination therapies presents growth opportunities.
Challenges include ongoing investigations into safety protocols and evaluation of patient outcomes.
Overall, MacroGenics' strategic plans and positive efficacy outcomes position them well for future growth and development.

MacroGenics reports stellar Q3 earnings, CEO transition announced

MacroGenics delivered impressive financial results in Q3 2024, marked by substantial revenue growth, increased net income, and a solid cash balance supported by strategic initiatives.
While facing challenges in managing rising expenses and navigating a CEO transition, the company's diverse clinical pipeline and strong financial position present opportunities for future growth and innovation.
Investors should monitor how MacroGenics addresses cost management, sustains operational momentum during leadership changes, and capitalizes on its strengths to drive continued success in the biopharmaceutical sector.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

MacroGenics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of antibody-based therapeutics for the treatment of cancer. Its product pipeline includes Margetuximab, Flotetuzumab, Retifanlimab, Enoblituzumab, Tebotelimab, MGC018, MGD019, IMGC936, and MGD014 for infectious diseases. The company was founded by Scott E. Koenig, Jeffrey V. Ravetch, LeRoy E. Hood, Ruedi Aebersold, and Alan Aderem on August 14, 2000 and is headquartered in Rockville, MD.

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $75,000 In MacroGenics To Contact Him Directly To Discuss Their Options If you suffered losses exceeding $75,000 in MacroGenics between March 7, 2024 to May 9, 2024 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330  (Ext. 1310). [You may also click here for additional information] NEW YORK , Sept.

Faruqi & Faruqi Reminds MacroGenics Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of September 24, 2024 - MGNX

NEW YORK, NY / ACCESSWIRE / September 17, 2024 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against MacroGenics, Inc. ("MacroGenics" or "the Company") (NASDAQ:MGNX) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired MacroGenics securities between March 7, 2024, and May 9, 2024, inclusive (the "Class Period").

MGNX SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that MacroGenics, Inc. Shareholders Have Opportunity to Lead Class Action Lawsuit!

LOS ANGELES , Sept. 17, 2024 /PRNewswire/ -- The DJS Law Group reminds investors of a class action lawsuit against MacroGenics, Inc. ("MacroGenics" or "the Company") (NASDAQ: MGNX) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.

MacroGenics, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - MGNX

NEW YORK, NY / ACCESSWIRE / September 16, 2024 / If you suffered a loss on your MacroGenics, Inc. (NASDAQ:MGNX) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/macrogenics-inc-lawsuit-submission-form?prid=103064&wire=1 or contact Joseph E. Levi, Esq.

Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of September 24, 2024 in MacroGenics Lawsuit – MGNX

NEW YORK , Sept. 16, 2024 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of stock or sellers of puts of MacroGenics, Inc. (NASDAQ: MGNX) between March 7, 2024 and May 9, 2024, both dates inclusive (the "Class Period"), of the important September 24, 2024 lead plaintiff deadline.

MGNX Deadline: MGNX Investors with Losses in Excess of $100K Have Opportunity to Lead MacroGenics, Inc. Securities Fraud Lawsuit

NEW YORK, Sept. 16, 2024 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of stock or sellers of puts of MacroGenics, Inc. (NASDAQ: MGNX) between March 7, 2024 and May 9, 2024, both dates inclusive (the “Class Period”), of the important September 24, 2024 lead plaintiff deadline.

ROSEN, TRUSTED INVESTOR COUNSEL, Encourages MacroGenics, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important September 24 Deadline in Securities Class Action – MGNX

NEW YORK, Sept. 16, 2024 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in MacroGenics, Inc. ("MacroGenics" or the "Company") (NASDAQ: MGNX) of a class action securities lawsuit.

September 24, 2024 Deadline: Contact Levi & Korsinsky to Join Class Action Suit Against MGNX

RADNOR, Pa.--(BUSINESS WIRE)---- $MGNX #classaction--The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) informs investors that a securities class action lawsuit has been filed in the United States District Court for the District of Maryland against MacroGenics, Inc. (“MacroGenics”) (NASDAQ: MGNX) on behalf of investors who purchased MacroGenics stock or sold MacroGenics puts between March 7, 2024 to May 9, 2024, inclusive (the “Class Period”). The lead plaintiff deadline is September 24, 2024. CONT.

Investor Reminder (MGNX):  Kessler Topaz Meltzer & Check, LLP Reminds MacroGenics, Inc.  Investors of September 24, 2024 Deadline

NEW YORK, NY / ACCESSWIRE / September 16, 2024 / If you suffered a loss on your MacroGenics, Inc. (NASDAQ:MGNX) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/macrogenics-inc-lawsuit-submission-form?prid=102966&wire=1 or contact Joseph E. Levi, Esq.

Shareholders of MacroGenics, Inc. Should Contact Levi & Korsinsky Before September 24, 2024 to Discuss Your Rights - MGNX

NEW YORK, NY / ACCESSWIRE / September 16, 2024 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against MacroGenics, Inc. ("MacroGenics" or "the Company") (NASDAQ:MGNX) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired MacroGenics securities between March 7, 2024, and May 9, 2024, inclusive (the "Class Period").

MGNX INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that MacroGenics, Inc. Stockholders Have Opportunity to Lead Class Action Lawsuit!

NEW YORK, NY / ACCESSWIRE / September 16, 2024 / If you suffered a loss on your MacroGenics, Inc. (NASDAQ:MGNX) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/macrogenics-inc-lawsuit-submission-form?prid=102892&wire=1 or contact Joseph E. Levi, Esq.

Levi & Korsinsky Announces the Filing of a Securities Class Action on Behalf of MacroGenics, Inc. (MGNX) Shareholders

NEW YORK , Sept. 16, 2024 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of MacroGenics, Inc. (NASDAQ: MGNX).

The Gross Law Firm Announces the Filing of a Securities Class Action on Behalf of MacroGenics, Inc.(MGNX) Shareholders

NEW YORK, NY / ACCESSWIRE / September 15, 2024 / If you suffered a loss on your MacroGenics, Inc. (NASDAQ:MGNX) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/macrogenics-inc-lawsuit-submission-form?prid=102833&wire=1 or contact Joseph E. Levi, Esq.

Levi & Korsinsky Notifies Shareholders of MacroGenics, Inc.(MGNX) of a Class Action Lawsuit and an Upcoming Deadline

SAN FRANCISCO, Sept. 15, 2024 (GLOBE NEWSWIRE) -- Hagens Berman urges MacroGenics, Inc. (NASDAQ: MGNX) investors who suffered substantial losses to submit your losses now.

MacroGenics (MGNX) Investors Alerted to September 24th Deadline in Securities Class Action, Encouraged to Contact Hagens Berman

NEW YORK, NY / ACCESSWIRE / September 15, 2024 / If you suffered a loss on your MacroGenics, Inc. (NASDAQ:MGNX) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/macrogenics-inc-lawsuit-submission-form?prid=102797&wire=1 or contact Joseph E. Levi, Esq.

Lost Money on MacroGenics, Inc.(MGNX)? Join Class Action Suit Seeking Recovery - Contact Levi & Korsinsky

RADNOR, PA / ACCESSWIRE / September 15, 2024 / The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) informs investors that a securities class action lawsuit has been filed in the United States District Court for the District of Maryland against MacroGenics, Inc. ("MacroGenics") (NASDAQ:MGNX) on behalf of investors who purchased MacroGenics stock or sold MacroGenics puts between March 7, 2024 to May 9, 2024, inclusive (the "Class Period" The lead plaintiff deadline is September 24, 2024. CONTACT KESSLER TOPAZ MELTZER & CHECK, LLP: If you suffered MacroGenics losses, you may CLICK HERE or go to: https://www.ktmc.com/new-cases/macrogenics-inc?utm_source=PR&utm_medium=link&utm_campaign=mgnx&mktm=r You can also contact attorney Jonathan Naji, Esq.

MGNX Investor Alert: A Securities Fraud Class Action Lawsuit Has Been Filed Against MacroGenics, Inc.

LOS ANGELES, CA / ACCESSWIRE / September 15, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against MacroGenics, Inc. ("MacroGenics" or "the Company") (NASDAQ:MGNX) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between March 7, 2024 and May 9, 2024, inclusive (the "Class Period"), are encouraged to contact the firm before September 24, 2024.

MacroGenics Inc Is Being Sued For Violating Securities Laws And Impacted Shareholders Are Urged To Contact The Schall Law Firm

NEW YORK, NY / ACCESSWIRE / September 15, 2024 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against MacroGenics, Inc. ("MacroGenics" or "the Company") (NASDAQ:MGNX) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired MacroGenics securities between March 7, 2024, and May 9, 2024, inclusive (the "Class Period").

MGNX INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that MacroGenics, Inc. Shareholders Have Opportunity to Lead Class Action Lawsuit!

ROCKVILLE, MD, Sept. 15, 2024 (GLOBE NEWSWIRE) --  MacroGenics, Inc. (NASDAQ: MGNX), a biopharmaceutical company focused on discovering, developing, manufacturing and commercializing innovative antibody-based therapeutics for the treatment of cancer, today presented updated efficacy and safety results from the TAMARACK Phase 2 study of vobramitamab duocarmazine (vobra duo), an antibody-drug conjugate (ADC) that targets B7-H3, for patients with metastatic castration-resistant prostate cancer (mCRPC). The data were featured in a poster presentation at the European Society for Medical Oncology (ESMO) Congress, taking place in Barcelona, Spain from September 13-17, 2024.

MacroGenics Announces Updated Efficacy & Safety Data from TAMARACK Phase 2 Study of Vobra Duo in mCRPC Patients at ESMO Congress 2024

LOS ANGELES, CA / ACCESSWIRE / September 14, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against MacroGenics, Inc. ("MacroGenics" or "the Company") (NASDAQ:MGNX) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between March 7, 2024 and May 9, 2024, inclusive (the "Class Period"), are encouraged to contact the firm before September 24, 2024.

The Schall Law Firm Invites Investors To Participate In A Securities Fraud Case Against MacroGenics, Inc.

RADNOR, PA / ACCESSWIRE / September 14, 2024 / The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) informs investors that a securities class action lawsuit has been filed in the United States District Court for the District of Maryland against MacroGenics, Inc. ("MacroGenics") (NASDAQ:MGNX) on behalf of investors who purchased MacroGenics stock or sold MacroGenics puts between March 7, 2024 to May 9, 2024, inclusive (the "Class Period" The lead plaintiff deadline is September 24, 2024. CONTACT KESSLER TOPAZ MELTZER & CHECK, LLP: If you suffered MacroGenics losses, you may CLICK HERE or go to: https://www.ktmc.com/new-cases/macrogenics-inc?utm_source=PR&utm_medium=link&utm_campaign=mgnx&mktm=r You can also contact attorney Jonathan Naji, Esq.

MacroGenics, Inc. Deadline Approaching: Kessler Topaz Meltzer & Check, LLP Reminds MacroGenics, Inc. Investors of Deadline in Securities Fraud Class Action Lawsuit

NEW YORK, NY / ACCESSWIRE / September 13, 2024 / If you suffered a loss on your MacroGenics, Inc. (NASDAQ:MGNX) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/macrogenics-inc-lawsuit-submission-form?prid=102569&wire=1 or contact Joseph E. Levi, Esq.

Shareholders that Lost Money on MacroGenics, Inc. (MGNX) Should Contact Levi & Korsinsky About Pending Class Action - MGNX

SAN FRANCISCO, CA / ACCESSWIRE / September 13, 2024 / Hagens Berman urges MacroGenics, Inc. (NASDAQ:MGNX) investors who suffered substantial losses to submit your losses now. Class Period: Mar. 7, 2024 - May 9, 2024 Lead Plaintiff Deadline: Sept.

MacroGenics (MGNX) Investors with Substantial Losses Encouraged to Contact Hagens Berman Before September 24th Deadline in Securities Class Action

LOS ANGELES, CA / ACCESSWIRE / September 13, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against MacroGenics, Inc. ("MacroGenics" or "the Company") (NASDAQ:MGNX) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between March 7, 2024 and May 9, 2024, inclusive (the "Class Period"), are encouraged to contact the firm before September 24, 2024.

MacroGenics Inc Is Being Sued For Securities Law Violations And Shareholders Are Urged To Contact The Schall Law Firm

NEW YORK, NY / ACCESSWIRE / September 13, 2024 / If you suffered a loss on your MacroGenics, Inc. (NASDAQ:MGNX) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/macrogenics-inc-lawsuit-submission-form?prid=102479&wire=1 or contact Joseph E. Levi, Esq.

News for MacroGenics Stock (MGNX)